So far, three major problems have kept GLP-1 drugs injectable rather than oral: enzymatic degradation, poor bioavailability, and the sheer cost of manufacturing
In the case of glucocorticoids, both excess (Cushings syndrome) and insufficiency (Addisons disease) contribute to oxidative stress through a variety of mechanisms, such as decreased antioxidant defenses, increased reactive oxygen species (ROS) generation, and impaired mitochondrial function, which ultimately results in chronic inflammation
So its been studied in inflammatory bowel diseases like Crohns disease and ulcerative colitis, ankylosing spondylitis, multiple sclerosis, lupus, psoriasis, lichen planus, type 1 diabetes, and Hashimotos [disease], fibrositis
Typically, this is done via IV drip infusion therapy at a wellness clinic, where the NAD+ solution is introduced into the bloodstream over the course of a couple of hours